Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains genomic testing in finding patients for the clinical trial, STARTRK-2. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
STARTRK-2: A Phase II Study on Use of Entrectinib in NTRK1/2/3, ROS1, or ALK Gene Fusions
Advertisement